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1. General summary 
Schizophrenia is a chronic, devastating mental illness, affecting approximately 1 % of 
the average population around the world. Research on etiology, symptomatology, and 
therapeutic possibilities has gone through a revolutionary change due to modern neuroimaging 
techniques and molecular genetic methods. 
The most known neurochemical model of schizophrenia is the dopamine (DA) theory 
(Carlsson & Lindqvist, 1963), which had an essential contribution to innovative trends in the 
development of new antipsychotics. Experiences coming from treatment with atypical 
antipsychotics, which are equally effective as compared to conventional neuroleptics but 
cause much less extrapyramidal side effects (EPS), contribute to the continuous modernization 
of the classical DA hypothesis. According to the revised DA theory, the most persistent 
cognitive deficit and the negative symptoms are related to the hypoactivity of the dorsolateral 
prefrontal cortex (DLPFC), while the positive symptoms during acute episodes are related to 
the hyperactivity of the ventral striatal elements of the DA system (Lieberman et al., 1997). 
The two disturbances are in causal relationship by means of extensive dopaminergic and 
glutamatergic connections between these structures (Weinberger et al., 2001). In the course of 
schizophrenia, more chronic recurrences of intermittent sensitized states of the subcortical DA 
system may occur. In these sensitive states, dopaminergic neurons are hyperresponsive to 
environmental stimuli and exposure to even moderate levels of stress, which are eventually 
associated with excessive DA release in the ventral striatum (n. accumbens) (Laruelle, 2000). 
This phenomenon is observable during active phases of the illness, but not in stable remission. 
Thus, the hyperdopaminergic state is phase-dependent, while "hypofrontality" is more 
persistent. 
Trends in schizophrenia research include three new directions regarding the dopamine 
hypothesis: (i) relationship between cognitive impairments and DA dysfunctions, (ii) 
relationship between DA receptors as evaluated by neuroimaging methods and 
clinical/cognitive parameters, (iii) the role of genetic variants of molecules of the DA system 
(e.g. receptors and transporters) in clinical symptoms, cognitive performance, and therapeutic 
response. These general issues were targeted by this thesis. 
One of the most fundamental functions of the human visual system is that we are able 
to discriminate stimuli from their background using luminance differences: the contrast 
between the stimulus and its background. Visual contrast sensitivity (VCS) functions are 
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modulated by DA (Masson et al., 1993). In hypodopaminergic states evolved from different 
origins, contrast sensitivity is reduced at low and medium spatial frequencies (Bodis-Wollner 
et al., 1987; Kéri et al., 1998), which suggests that the measurement of VCS as a peripheral, 
non-invasive method seems to be a useful tool to detect the state of the DA system. In our first 
experiment, we tested the effect of the high and the low dose of quetiapine, an atypical 
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antipsychotic, on DA system by using three independent methods: (i) I-iodobenzamide 
single photon emission computer tomography (123I-IBZM SPECT) (ii) clinical symptom 
scales, and (iii) VCS. In addition, we identified a subgroup of clinically stable patients with 
high risk of relapse in the course of a six months follow-up period. All of the three methods 
confirmed that quetiapine has low antidopaminergic potential even in the high-dose condition. 
The patients with decreased striatal 123I-IBZM uptake showed worsening of psychotic 
symptoms during the follow-up period. We hypothesize that it was caused by the persisting 
hyperactivity of the striatal dopaminergic system even after apparent clinically improvement. 
The heritability of schizophrenia is well illustrated by a higher risk of morbidity 
among biological relatives of patients as compared to the general population. The risk ratio for 
schizophrenia relatives correlates with the degree of relationship (Tsuang, 2000). Association 
and linkage studies intended to find out the susceptibility genes excluded the possibility of 
monogenic forms of inheritance. The transmission is attributable to complex polygenic 
factors. Neuropharmacological and neurochemical investigations demonstrating several 
anomalies in the monoamine neurotransmission, particularly for the DA and serotonin (5-HT) 
systems, have stimulated a series of association studies. The relationship between 
schizophrenia and the dopamine D3 receptor (DRD3) gene Ser9Gly polymorphism has 
previously been demonstrated (Dubertret et al., 1998). Changes in the amino acid sequence 
could modify the function of the receptor, which may result in critical changes in the clinical 
phenotype such as symptoms and cognitive profile and response to antipsychotic medication. 
The more frequent occurrence of Ser9 allele in non-responder groups of schizophrenic 
patients has been published earlier (Shaikh et al., 1996; Scharfetter et al., 1999), which has not 
been confirmed by Malhotra and coworkers (1998). In our second study, we investigated the 
relationship between DRD3 gene Ser9Gly polymorphism, cognitive functions and response to 
atypical antipsychotic medication. Our results suggest that more severe impairments in 
prefrontal executive functions and worse therapeutic response are associated with the Ser9Ser 
genotype and the Ser9 allele. 
According to the neurodevelopmental hypothesis of schizophrenia, genetic and/or 
environmental factors disrupt early central nervous system development, producing long-term 
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vulnerability to normal developmental processes (e.g. synaptic pruning during 
preadolescence) and to stress events that then lead to manifest psychotic symptoms (Maynard 
et al., 2001). Normal development, migration, differentiation and survival of neuronal cells, 
including dopaminergic neurons, depend on the timed activation of trophic factors that are 
genetically determined (Guillin et al., 2001). An important representative of these factors is 
the brain-derived neurotrophic factor (BDNF), which has multiple roles in developmental 
processes (Webster et al., 2002). In addition, BDNF specifically influences the expression of 
dopamine D3 receptors, which may link the dopamine and neurodevelopmental theories of 
schizophrenia. Therefore, it is plausible to hypothesize, that genetic variants of BDNF and 
schizophrenia may be associated. We sought the occurrence of a recently found single 
nucleotide substitution (C270T) polymorphism of BDNF in schizophrenia (Kunugi et al., 
2001). The mutated type T allele and the C270T genotype were significantly more frequent in 
the patient (13.9 % and 25.7 %) compared with the controls (2.9 % and 5.9 %), suggesting 
that the T allele may contribute to susceptibility to schizophrenia. Table 1 shows overview of 
experiments. 
Table 1. Overview of experiments underlying the thesis 
Investigation of striatal dopamine 
functions 
123I-IBZM SPECT 
Measure of visual contrast sensitivity 
Clinical examinations 
Investigation of genetic effects 
DRD3 Ser9Gly & DAT 9/10 
VNTR polymorphism 
association analysis 
cognitive performance 
response to treatment 
BDNF C270T polymorphism association analysis 
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2. Introduction 
2.1. Investigation of receptor functions and antipsychotic actions 
2.1.1. Neuroimaging techniques 
The classical DA hypothesis of schizophrenia suggests that the hyperactivity of the DA 
system is responsible for the psychotic symptoms of the disease (Carlsson & Lindqvist, 1963). 
The initial concept was based on indirect observations. The principle has risen from the facts 
that agonists of dopamine D2 receptor (DRD2) may provoke psychotic symptoms (Angrist & 
Gershon, 1970) and that antipsychotic compounds have dose-related DA receptor antagonist 
features (Creese et al., 1976). Clinical efficacy of neuroleptics was selectively related to the 
blockade of DRD2 in contrast to their effect on any other neurotransmitter system (Peroutka 
& Snyder, 1980). Progress in functional neuroimaging techniques has allowed the justification 
of the in vitro results under in vivo circumstances and the refinement of the DA hypothesis as 
well. The SPECT method using eligible ligands labeled with radio-isotopes such as I-IBZM 
([(S)-2-hydroxy-3-iodo-6-methoxy-JV-[(l-ethyl-2-pyrrolidinyl)methyl]benzamide]) which 
binds selectively to striatal DRD2 (Kung et al., 1990), is suitable for the visualization of the 
mechanism of antipsychotic effects. This method is also suitable for the exploration of the 
functional disturbances of the DA system which may play a key role in the etiology of 
schizophrenia. According to the modified DA hypothesis, the elements of the DA system 
simultaneously show hyper-, and hypoactivity in the schizophrenic brain. Pathologically low 
activity in the prefrontal cortex is responsible for the cognitive deficit and, at the same time, 
this causes the mesolimbic-striatal hyperactivity (Davis et al., 1991). Regulation of the striatal 
DA release has two components (Grace, 1991). The sustained or tonic mechanism mediates 
the background DA activity, which is mainly modulated by glutamatergic projections from the 
prefrontal cortex, while the phasic component refers to action potentials of DA neurons in 
response to environmental stimuli (Byne & Davis, 1999). During the long-term course of 
schizophrenia, a chronic recurrence of hyperresponsive states of subcortical DA systems may 
occur which expires during remission. In these sensitive states, DA neurons are hyperreactive 
to different environmental stimuli and even moderate level of stress could lead to relapse of 
psychotic symptoms. Hyperresponsivity is associated with exaggerated DA release. During 
1 
I-IBZM SPECT measurements, the increased amount of endogenous DA leads to a decrease 
in isotope activity as a consequence of competition between the labeled radioligand and DA 
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(Laruelle, 2000). Thus, acute periods of the illness are related to the hyperactivity of the 
limbic-striatal DA system, which is restored by DA receptor blockade caused by antipsychotic 
treatment. Several positron emission tomography (PET) (Farde et al., 1989) and SPECT 
studies (Klemm et al., 1996) investigated the mechanism of antipsychotic action in the brain. 
Neuroleptics having similarly strong DRD2 antagonist properties as their prototype 
chlorpromazine have been proven to be effective in the treatment of positive symptoms -
delusions, hallucinations, agitation - of schizophrenia. A threshold of at least 60% of DRD2 
occupancy has been postulated for clinical response (Nordstrom et al., 1993). However, the 
administration of "classical" antipsychotics, induce more or less severe extrapyramidal side 
effects (EPS) due to the nigrostriatal DA blockade. The neuroleptic threshold is around 75-
80% occupancy of DRD2, which means that further dose-dependent saturation of receptors 
does not enhance the therapeutic response, but significantly increase the rate of EPS (Farde et 
al., 1992). EPS accompanying the treatment is often serious, sometimes irreversible event, 
impeding the compliance of patients and hampering their quality of life. In the clinical 
practice, specific scales are in use for the measurement and monitoring of these signs and as 
well clinical symptoms. In our study, we used the Positive and Negative Syndrome Scale 
(PANSS) (Kay et al., 1987) to score the psychopathological signs, the Simpson Angus Scale 
(SAS) (Simpson & Angus, 1970) for assessment of the Parkinson-like features, and the 
Abnormal Involuntary Movements Scale (AIMS) (Fann et al., 1977) to evaluate tardive motor 
disturbances. 
Clozapine, a dibenzodiazepine derivate was the first antipsychotic drug having 
equivalent efficacy with that of classical compounds but had much lower propensity to induce 
EPS. In addition, clozapine has other advantages over typical antipsychotic agents, including 
efficacy in treatment-refractory states (Kane et al., 1988), against negative symptoms 
(affective blunting, alogia, avolition, and anhedonia), and certain types of cognitive deficits 
(Meltzer & McGurk, 1999). Neuroimaging studies revealed that at clinically effective doses 
clozapine induces lower DRD2 occupancy (Nordstrom et al., 1995). However, clozapine also 
has a considerable antagonistic effect on serotonin 5HT2A receptors (Farde et al., 1994). This 
"atypical" receptor affinity profile which may result in its unique clinical characteristics 
constituted the theoretical basis of the development of the new generation of antipsychotic 
compounds. One member of this new class is quetiapine. Several clinical investigations have 
confirmed its efficacy in the treatment of positive and negative symptoms and a better 
tolerability than that of clozapine (Wetzel et al., 1995; Arvanitis & Miller, 1997). Its receptor 
profile is somewhat similar to that of clozapine: in a wide range of dose quetiapine induces 
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only 24-28 % DRD2 occupancy (Kiifferle et al., 1997) and remarkably binds to 5HT2A 
receptors (Kapur et al., 2000). 
2.1.2. Measurement of visual contrast sensitivity and the dopamine system 
The main components of human visual information processing are the magnocellular 
(M) and parvocellular (P) pathways which are segregated from both functional and 
morphological points of view. The M pathways originated from the retina comprise large 
ganglion cells projecting to the magnocellular layers of the lateral geniculate nucleus and then 
to layer 4C alpha of the primary visual cortex. In contrast, the retinal origin of the P pathways 
includes small ganglion cells projecting to layer 4C beta of primary visual cortex through the 
parvocellular layers of the lateral geniculate nucleus. Although the M and P parallel pathways 
interact at the level of visual cortex, data suggest a definite functional separation even at 
higher levels of information processing. The M system (transient channels) is responsible for 
the analysis of motion and spatial location, whereas the P system (sustained channels) is 
related to the processing pattern and color (Bassi & Lehmkuhle, 1990). The sensitivity of the 
two systems is stimulus-dependent. The M system shows higher sensitivity for stimuli with 
low spatial frequencies (<3 cycles per degree of visual angle [c/d]) and high temporal 
frequencies (4-15 Hz), while the P system can be better stimulated with patterns having high 
spatial and low temporal frequencies (Wilson 1980). This feature allows biased investigation 
of each unit under certain circumstances. 
Luminance contrast is the difference in luminosity of a pattern against its background. 
The higher the contrast between them, the easier to recognize the stimulus. With a gradual, 
stepwise adjustment, we are able to measure the minimal contrast necessary for perceiving a 
stimulus. This is contrast threshold, and its reciprocal is visual contrast sensitivity (VCS). 
VCS is regularly evaluated using luminance-contrast gratings with a sinusoidal luminance 
profile. One cycle consists of a pair of a dark bar with minimal luminance and a white bar 
with maximal luminance. It is possible to change both spatial and temporal parameters of 
stimuli within a well-defined range. Spatial frequency is the number of cycles per 1° of visual 
angle (c/d). In the static condition, steady patterns are used. In the dynamic condition, dark 
and white bars change places several times during a second. The number of changes during a 
second defines temporal frequency (Hz). With this method different functional units of the 
visual system can be investigated (Campbell, 1983) (Figure 1). 
m Low spatial frequency 
— — 
Temporal modulation 
Figure 1. Spatiotemporal 
characteristics of visual 
stimuli. Brightness changes 
periodically to constitute 
dark and white bars with 
minimal and maximal 
luminance, respectively. 
The contrast is gradually 
decreased to define the 
minimal contrast which is 
indispensable for perceiving 
pattern. Contrast is defined 
by Michelson formula [C= 
(Lmax ~ L m i n ) / ( L m a x + Lm in)] . 
Spatial frequency is the 
number of cycles per 1° of 
visual angle (c/d). Temporal 
frequency is the number of 
phase reversals during a 
second (Hz). 
Sinusoidal grating 
with low contrast 
Sinusoidal grating 
with high contrast 
It has been well established that visual processing is modulated by DA (Masson et al., 
1993). A hypodopaminergic state present in Parkinson's disease is accompanied by VCS 
reduction at spatial frequencies up to 4.8 c/d (Bodis-Wollner et al., 1987). In the dynamic 
condition, VCS reduction was observed mainly at low frequencies, leading to the hypothesis 
of transient channel dysfunction in Parkinson's disease (Mestre et al., 1990). In case of 
schizophrenia, the results are controversial. Some findings suggest a transient channel 
dysfunction (Schwartz et al., 1987), while other studies concluded that both transient and 
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sustained channel functions are impaired in schizophrenia (Green et al., 1994; O'Donnel et al., 
1996). According to a recent study, the characteristics of VCS loss show relationship with the 
current symptoms. Patients with positive symptoms exhibited VCS deficit only at high spatial 
frequencies, whereas negative symptom patients showed reduced VCS at both low and high 
frequencies (Slaghuis, 1998). The results could be confounded by antipsychotic medication. 
Patients treated with conventional antipsychotics show parkinsonian VCS deficits related to 
the DA blockade (Bulens et al., 1989). The extent of impairment correlates with the daily dose 
of antipsychotics and with the severity of parkinsonian symptoms rated by SAS (Kéri et al., 
1998). In contrast, patients receiving the atypical antipsychotic olanzapine, which has a more 
favorable EPS profile, show intact VCS values over the whole spatial frequency range (Kéri et 
al., 1999). According to these findings, it may be hypothesized that hypodopaminergic states 
induced by pharmacogenic DA blockade or related to the negative symptoms of schizophrenia 
are associated with parkinsonian VCS impairment. 
Objective of the thesis: to study the relations between EPS measured by clinical rating 
scales, values of VCS and striatal DRD2 occupancy rates investigated by 123I-IBZM SPECT. 
2.2. Gene polymorphisms in schizophrenia 
2.2.1. Genetic research 
It is well established that schizophrenia has a hereditary component. Decades of 
research on genetic factors underlying schizophrenia revealed the polygenic manner of 
heritability, which means that susceptibility to the disease is linked to the interactions of 
several genes with small effect (McGuffin et al., 1995). Both linkage and association 
strategies have been applied in the search of genes that cause or predispose to schizophrenia. 
The basic principle of linkage approach is that attached transmission of neighboring genes is 
more probable than that of distant ones. Known genetic markers are inherited together with 
diseases and that refers to the localization of susceptibility genes. International linkage studies 
involving different samples have provided inconsistent results. Numerous genomic regions 
have been suspected to carry the predisposing genes: 6p24-22, 8p22-21, 22ql 1-12, 13ql4.1-
q32, 5q21-q31, 18p22-21, and 10pl5-pll (Schwab et al., 2000), but convincing evidence is 
still lacking (Owen, 2000). In contrast to linkage analysis, association approaches are based on 
the comparison of allelic frequencies of candidate genes in groups of patients and controls, 
and examine variants of suspected genes selected on the basis of their relevance to the putative 
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etiology and pathophysiology or other disease specific feature (Schwab et al., 2003). Many 
association studies have been carried out relying on the results of neuropharmacological and 
neurochemical investigations (Janka, 1995). Thus, genes encoding DA and 5-HT receptors 
became the main target for association studies. Some inconsistent associations have been 
proven between schizophrenia and the Ser9Gly polymorphism of the dopamine D3 receptor 
(DRD3) (Crocq et al., 1992; Spurlock et al., 1998) similarly to the T102C variant of the 
serotonin 5-HT2A receptor (Williams et al., 1996). Another group of candidate genes play a 
role in the development of nervous system. Polymorphism of these genes may contribute to 
the maldevelopment of neurons, synapses, and receptors. 
Polymorphisms may have diverse functional consequences, depending on the affected 
DNA site. For example, substitution in the amino acid sequence of a receptor may change the 
binding properties or association with intracellular signal processes. Localization in the 
promoter or enhancer region of a gene may lead to the modification of expression. Finally, the 
substitution of a nucleotide may be apparently silent but could change the stability of mRNA. 
2.2.2. Polymorphisms of dopamine D3 receptor and dopamine transporter genes 
The DRD3 is present in various areas of the central nervous system, including the 
limbic system (particularly the nucleus accumbens), the neocortex, and the cerebellum 
(Kerwin & Owen, 1999). It has a high affinity to both conventional and atypical 
antipsychotics, which also elevate the mRNA of DRD3 (Buckland et al., 1993). A recent 
study found 2-fold elevation in the mRNA level of the DRD3 in lymphocytes of schizophrenic 
patients (Ilani et al., 2001). The DRD3 gene is located on chromosome 3ql3.3. Its Ser9Gly 
polymorphism, close to the N-terminal of the protein, has been widely studied. The 
homozygote variants have twice higher affinity to DA than heterozygotes (Lundstrom & 
Turpin, 1996). Several case-control studies found association between schizophrenia and 
homozygosity with a special reference to the Ser9Ser homozygote genotype (Crocq et al., 
1992; Shaikh et al., 1996; Ebstein et al., 1997; Spurlock et al., 1998). However, negative 
results have also been published (Malhotra et al., 1998; Virgos et al., 2001). According to 
recent meta-analyses, the DRD3 Ser9Gly polymorphism confers weak but significant 
association with schizophrenia (Williams et al., 1998; Dubertret et al., 1998; Schwartz et al., 
2000). The Gly9Gly homozygote variant has been found to be associated with tardive 
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dyskinesia (Steen et al., 1997), akathisia (Eichhammer et al., 2000), and spontaneous 
dyskinesia in drug-naive schizophrenic patients (Lovlie et al., 2001). 
Several pharmacogenetic studies have investigated the relationship between Ser9Gly 
polymorphism and therapeutic response to clozapine. Shaikh et al. (1996) found that Ser9 
allele was significantly more frequent in patients than in controls (p=0.004). Both groups were 
of Caucasian origin. Regarding to response to treatment with clozapine (the criterion of 
responders was at least 20-point improvement in the Global Assessment Scale (GAF), the 
Ser9Ser genotype was more frequent among the non-responders (p=0.04) (Shaikh et al., 
1996). Another study conducted in Pakistani patients provided similar results: a better 
treatment response was related to the Gly9 allele (p=0.0058) and genotypes consisting of Gly9 
(Scharfetter et al., 1999). However, Malhotra et al. (1998) failed to replicate these results. 
They could confirm the association neither between excess DRD3 homozygosity and 
schizophrenia, nor DRD3 homozygosity and response to clozapine (Malhotra et al., 1998). 
One study suggested that the Gly9Gly genotype showed a trend toward an excess among non-
responders patients receiving typical neuroleptics (Joober et al., 2000). 
The dopamine transporter (DAT) eliminates released synaptic DA in the striatal 
regions, playing an important role in the regulation of subcortical DA neurotransmission. On 
the basis of findings published so far, there is no evidence of association between the 9/10 40-
bp variable number of tandem repeats (VNTR) polymorphism of the DAT and schizophrenia 
(Li et al., 1994; Maier et al., 1996; Inada et al., 1996). 
Cognitive impairment is an essential component of the phenomenology of 
schizophrenia. The most severely affected functions are executive and memory domains 
(Callicott et al., 2000; Gold et al., 1997). Executive functions include the utilization of 
information stored in working memory, planning, and flexible change of strategies basing on 
feedback. The Wisconsin Card Sorting Test (WCST) is widely used for the investigation of 
executive functions. During the test, cards depicting geometrical figures must be categorized 
according to their color, shape and number, consecutively. The criterion of completion of a 
category is 10 successive correct answers. Following this the investigator changes the rule of 
sorting without any warning, for example from color to shape. After the feedback of wrong 
choice, the participant should shift to the new categorization rule. Schizophrenic patients 
complete fewer categories than unaffected controls and fail to shift strategy: they continue to 
sort the cards according to the previous rule and are inclined to repeat false choices. Executive 
functions are related to the dorsolateral prefrontal cortex (DLPFC). In case of schizophrenia, a 
relationship has been demonstrated between impaired DLPFC activation and poor 
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performance on executive tasks (Weinberger et al., 1986; Bertolino et al., 2003). The 
structural bases of explicit memory functions are the temporo-hippocampal circuits, whereas 
implicit memory is housed in neocortical and striatal units. While implicit memory seems to 
be relatively preserved, deficits of explicit memory functions and also both macroscopic and 
microscopic impairments of temporal lobes and hippocampal structures are well established 
feature of schizophrenia. These alterations have been proven by neuropsychological and 
neuroimaging investigations (Friston et al., 1992; Andreasen et al., 1995; Lawrie & Abukmeil, 
1998; Kéri et al., 2000). These disturbances can be conceptualized as a failure of cognitive 
control which may be due to impairments in representing, maintaining, and updating context 
information. Dysfunctional interactions between the malfunctioning DA system and the 
prefrontal cortex can lead to abnormal gating of stimuli into the DLPFC producing such 
cognitive disturbances (Braver et al., 1999). 
Several studies have demonstrated the effect of different elements of DA system on 
cognitive functions. A Vall58Met functional polymorphism of the catechol-O-
methyltransferase (COMT) gene has been shown to affect executive performance and the 
physiology of the prefrontal cortex by influencing prefrontal dopamine signaling. The COMT 
valine allele is associated with relatively poor prefrontal function and may increase the risk for 
schizophrenia (Egan et al., 2001). It has been also demonstrated that elevated density of the 
dopamine D1 receptors in DLPFC of schizophrenic patients, which seems to be compensatory 
upregulation secondary to sustained deficiency in mesocortical DA function, correlated with 
poorer working memory performance (Abi-Dargham et al., 2002). Conventional 
antipsychotics having remarkable DRD2 antagonist effect can further worsen cognitive 
functions, but atypicals with high 5-HT/DA affinity ratio seem to improve verbal learning 
abilities, working memory, and visuo-motor functions (Keefe et al., 1999; Gallhofer et al., 
1999). 
Objective of the thesis: to investigate the effects of DRD3 Ser9Gly and DAT VNTR 
polymorphisms on therapeutic response to atypical antipsychotics as well as on cognitive 
functions assessed by WCST and verbal memory performance in schizophrenia. 
2.2.3. Brain-derived neurotrophic factor gene polymorphism 
According to the neurodevelopmental hypothesis of schizophrenia, abnormal events 
during early phases of development lead to altered differentiation, migration, and survival of 
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neurons (Weinberger, 1987). This early neurodevelopmental theory supposes that further 
specific developmental events, which occur during subsequent decades, make interactions 
with prenatal maldevelopmental processes creating manifestations of the disease. The late 
neurodevelopmental hypothesis focuses on the role of abnormal synaptic elimination 
appearing in late adolescence (Tenyi & Trixler, 1999). Eventually, changes in synaptic 
transmission in specific neural circuits result in impaired morphology and physiology, leading 
to different pathologic process (e.g. pathologic pruning), which manifest in the clinical onset 
of the disease (Mimics et al., 2001). Many researches have been focused on neurotrophic 
factors due to their widespread role in modulating many kinds of different developmental 
events (Arnold & Rioux, 2001). These proteins are the molecular regulators of synaptic 
plasticity, turning neuronal activity to functional and structural changes (McAllister et al., 
1999). Therefore, their genetic variants with changed functions may result in an increased risk 
for abnormal developmental processes. Within the family of neurotrophic factors, brain-
derived neurotrophic factor (BDNF) is the most predominantly expressed in the human 
postnatal brain, with the highest mRNA levels in neocortex and hippocampal formations 
(Wetmore et al., 1990). The level of BDNF mRNA shows characteristic changes during 
postnatal development: it increases one-third from infancy to adulthood, a period believed to 
be critical regarding both neuronal maturation and onset of schizophrenia (Webster et al., 
2002). BDNF influences the growth of almost each central neurotransmitter system, stimulates 
cholinergic (Knipper et al., 1994) and glutamatergic transmission (Takei et al., 1997), 
promotes the survival of basal forebrain cholinergic neurons, ventral mesencephalic 
dopaminergic neurons, and serotonin neurons (Mamounas et al., 2000; Hyman et al., 1991). 
According to recently published data, BDNF regulates the expression of DRD3 in the nucleus 
accumbens through DA and BDNF secreting neurons, originated from ventral tegmental area 
(Guillin et al., 2001). 
Post mortem studies have found elevated levels of BDNF in the anterior cingulate 
cortex and hippocampus of schizophrenic patients (Takahashi et al., 2000). Others showed 
increased BDNF concentrations in cortical areas and a significant decrease of this 
neurotrophin in the hippocampus of patients (Durany et al., 2001). BDNF levels were 
significantly reduced in the serum of schizophrenic patients (Toyooka et al., 2002). Neonatal 
ventral hippocampal lesion as an animal model of the neurodevelopmental hypothesis 
suppressed BDNF mRNA expression in the dentate gyrus and tended to reduce its expression 
in the prefrontal cortex (Lipska et al., 2001). Animals with neonatal ibotenic acid lesions of 
the ventral hippocampus have reduced basal levels of BDNF mRNA (Ashe et al., 2002). 
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The BDNF gene is located on chromosome Ilpl3-pl4. Several polymorphisms of 
BDNF gene are known. Studies searching for an association between the dinucleotide repeat 
polymorphism (166-221 bp) and schizophrenia provided negative results (Hawi et al., 1998; 
Virgos et al., 2001). However, an excess of the 172-176 bp alleles was found in patients with 
late onset, in neuroleptic-responding patients and in non-substance-abusing patients (Krebs et 
al., 2000). The investigation of the Val66Met polymorphism of the BDNF gene also failed to 
show association with schizophrenia (Egan et al., 2003). However, a recent family-based 
study including a larger sample revealed significant association between BDNF 
polymorphism and schizophrenia (Muglia et al., 2003). 
A recently identified single nucleotide polymorphism of the BDNF gene is a C270T 
substitution in the 5'-noncoding region in which the T270 is the mutated type. The T270 has 
been found to be significantly more frequent in patients with late-onset Alzheimer disease 
than in age-matched healthy controls (Kunugi et al., 2001). 
Objective of the thesis: to analyze a putative relationship between BDNF C270T 
polymorphism and schizophrenia, and to compare the clinical and psychosocial characteristics 
of patients with different genotypes. 
3. Subjects and methods 
3.1. Receptor functions 
3.1.1. Schedule of experiment 
We performed two sets of experiments in schizophrenic patients receiving quetiapine. 
The treatment of the patients started after their admission to the inpatient unit of the 
Psychiatric Department due to their acutely ill state. The first examination was performed 
after the stabilization of their state following at least 3 weeks of monotherapy with quetiapine 
on constant dose ("high dose" condition). The second measurement was carried out when the 
patients had been continuously receiving the constant maintenance dose of quetiapine at least 
for 3 weeks. The maintenance dose was achieved by tapering the higher daily dose to a lower 
dose which fit better to the stable clinical state. Each experiment included clinical 
examination, measurement of VCS, and 123I-IBZM SPECT procedure. The trial was 
accomplished by a 6 months follow-up period (Figure 2). 
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Figure 2. Schedule of investigation of dopamine D2 receptor functions in 
schizophrenia 
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2.1.2. Subjects 
Ten patients (7 women, 3 men) with DSM-IV diagnosis of schizophrenia participated 
in the study. Their age was 34 ±7 years (mean ±SD). The patients were recruited from the 
inpatient unit of the Department of Psychiatry, University of Szeged. Written informed 
consent was obtained from each subject before enrolment. All subjects received a thorough 
psychiatric, medical and neurological evaluation, including brain CT to rule out structural 
lesions. All patients were free of active medical problems or substance abuse. None of the 
patients had been treated with long-acting depot neuroleptic medications during at last a 3 
month-period before the study. The PANSS was used to evaluate the clinical symptoms. 
Extrapyramidal signs were rated by SAS and AIMS. Clinical and demographical details of the 
participants are given in Table 2. 
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Table 2. Demographical and clinical data of schizophrenia patients 
Patient PANSS1 Interval 
Quetiapine 
dose SAS
2 AIMS3 
to (mg/day) 
Numbe 
r 
Gende 
r 
Ag 
e 
Ist 2nd changes relapse 
relapse 
(weeks) 1st 2nd 1st 2nd Is* 2nd 
1. F 45 74 74 0 - - 400 200 10 10 0 0 
2. F 39 93 96 3 - - 800 400 16 16 11 12 
3. F 30 52 56 4 110 5 400 200 10 10 1 1 
4. M 27 98 86 12 - - 600 300 10 10 0 0 
5. M 30 114 108 -6 111 14 800 400 14 13 0 0 
6. F 34 53 55 2 88 35 400 200 10 10 0 0 
7. F 38 67 46 -21 98 11 600 300 10 10 4 3 
8. F 35 65 65 0 128 20 600 300 13 11 0 0 
9. F 43 82 76 -6 - - 600 300 10 10 0 0 
10. M 23 64 55 -9 - - 600 300 10 10 0 0 
1 2 3 
Positive and Negative Syndrome Scale for Schizophrenia, Simpson-Angus Scale, Abnormal 
Involuntary Movement Scale 
3.1.3. Visual contrast sensitivity procedure 
Visual patterns were generated by using a standard Venus system (Neuroscientific 
Corporation, USA). Stimuli were vertical luminance-contrast gratings with sinusoidal 
luminance profile. Two temporal frequencies (0 Hz in the static test, 8 Hz in the dynamic test) 
and 9 spatial frequencies (0.5, 1.2, 1.9, 2.9, 3.6, 4.8, 5.7, 7.2, and 14.4 c/d) were included. The 
stimulus display subtended 13° x 13° from a viewing distance of 1 m. A trial consisted of two 
consecutive observation periods, each initiated by a brief tone. The duration of an observation 
period was 1 s. The grating was presented randomly either in the first or the second 
observation period immediately after the initiating tone. The subject's task was to indicate 
whether the stimulus appeared after the first or second tone by pressing one of the two 
response buttons on a separate response pad. The exposure time of the gratings was 500 ms. 
Responses were accepted from the onset of a stimulus up to 10s after the completion of the 
trial. The next trial was not initiated without a response. At the beginning, the contrast was set 
at 10 dB above the normal values. The computer automatically decreased or increased the 
contrast by 3 dB when the subject gave, respectively, 2 right or 2 wrong consecutive responses 
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at a given spatial frequency. If a pair of correct or wrong responses was given, the computer 
repeated the measurement without the modification of the contrast level. The contrast 
threshold was the minimal contrast level at which subjects were able to give 2 consecutive 
correct responses. Analysis of variance (ANOVA) was used for statistical analysis of VCS 
values received at different dose levels of quetiapine. 
3.1.4. SPECTprocedure 
During the SPECT procedure, 60 minutes after oral administration of 450 mg 
potassium-perchlorate, the patient was given 185 MBq 123I-IBZM (Cygne BV, Holland) 
intravenously. The SPECT data acquisition was started 90 minutes after the IBZM injection. 
For this a rotating single head gamma camera with low energy high-resolution collimator 
(Siemens Diacam) connected to a computer system (Siemens Icon) was used. Data were 
collected for 120 projections (360° rotation) in 128x128 matrix. The acquisition times were 30 
seconds per projection. Images were reconstructed by filtered backprojection using a 
Butterworth filter with a cut-off frequency of 0.5 Nyquist, power factor 10. The reconstructed 
images were corrected for gamma ray attenuation using the Chang method with an attenuation 
coefficient of 0.12cm"1. 
The reconstructed slices were visually assessed by three well-trained observers and 
semi-quantitatively evaluated. The observers were blind to the medication status of the 
subject. In three consecutive transversal slices with the highest I-IBZM uptake at the level 
of striatum, striatum/occipital lobe activity ratios were calculated and averaged separately on 
the left and right side. The ratios were calculated using region of interest (ROI) method. 
Elliptical ROI-s were placed on the consecutive transversal slices at the level of basal ganglia 
with the highest uptake of the striatum. The region size of striatum and the region size of the 
occipital lobe were 100 ±20 pixels and 47 ±6 pixels, respectively. Two independent nuclear 
medicine specialists tested the reproducibility of the method used for determining the ratio. 
The ratios calculated by the two evaluators were statistically not different and correlated well 
(p=0.053). 
For the evaluation of the experimental data, statistical analysis was performed by two-
tailed /-test and correlations were calculated by Pearson method. The significance level was 
set at/?<0.01. 
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3.2. Dopamine D3 receptor Ser9Gly polymorphism and dopamine transporter variable 
number of tandem repeats (VNTR) polymorphism 
3.2.1. Subjects 
Altogether 120 Caucasian volunteers participated in the study. Seventy-five of them 
(34 men and 41 women) received the DSM-IV diagnosis of schizophrenia (APA, 1994) and 
45 (17 men and 28 women) were healthy controls who were recruited from the hospital staff 
and general population. Clinical symptoms were evaluated with the PANSS and the Global 
Assessment of Functioning (GAF) scale (APA, 1994). Participants also received the Mini 
International Neuropsychiatric Interview Plus (MINI Plus) (Balazs & Bitter, 2000). From the 
whole sample, 36 patients (14 men and 22 women) and 20 matched control subjects (8 men 
and 12 women) were included in the neuropsychological assessment (Table 3). The patients 
received atypical antipsychotics at least for 12 weeks (clozapine: n=5, olanzapine: n=29, 
quetiapine: n=16, risperidone: n=25). The treatment was initiated during an acute psychotic 
episode, which resulted in a substantial drop in community functions and required 
hospitalization. A detailed overview of medical documentation (diagnosis, symptom ratings, 
and medication) was carried out by an expert psychiatrist who was blind to the results of 
genotyping and neuropsychological assessment. In addition, each patient was interviewed 
individually. A patient was considered responder if there was an improvement of 20 points or 
more in the GAF scale during the treatment period. All participants gave their informed 
consent. 
3.2.2. Genetic analysis 
Genomic DNA was extracted from peripheral blood leukocytes. In the case of DRD3, 
the polymerase chain reaction (PCR) (Progene, Techne Cambridge) was carried out with the 
following primers: 5' - GCT CTA TCT CCA ACT CCT ACA - 3' and 5' - AAG TCT ACT 
CAC CTC CAG GTA - 3'. 100 ng of genomic DNA was amplified in 25 pi reaction mixture 
[1.5 mM MgCl2 (Boehringer Mannheim), 100 pM of each dNTP (dATP, dCTP, dGTP, dTTP) 
(Boehringer Mannheim), 5 pM of each primer (Creative Lab), 0.5 mM dithiothreitol (Sigma), 
0.01% gelatin (Sigma), 1.5 U Taq polymerase (Sigma)]. The PCR protocol included a 
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denaturation of DNA (95°C for 6 min) and 35 cycles with the following steps: 92°C for 1 min, 
56°C for 1 min, 72°C for 1 min. The final extension was 72°C for 8 min. The PCR product 
was digested with 1 U MscI/15 pi (GibcoBRL). The electrophoresis was carried out on 5% 
acrylamide/bis acrylamide gel (BioRad). In the case of DAT, PCR amplification was carried 
out with the following primers: DATVNTRF: 5' - TGT GGT GTA GGG AAC GGC CTG 
AG - 3' and DATVNTRR: 5' - CTT CCT GGA GGT CAC GGC TCA AGG - 3'. 100 ng 
genomic DNA was used for PCR reaction in 25 pi reaction mixture (1.3 mM MgCL, 200 pM 
dNTP mix, 0.25 pM of each primer, 5% DMSO, 1.5 U Taq polymerase). The PCR program 
included the following steps: denaturation of DNA (5 min at 94°C), 30 cycles of 30 sec at 
94°C, 30 sec at 62°C, and 30 sec at 72°C. This was followed by the final extension for 10 min 
at 72°C. The electrophoresis was carried out on 8% acrylamide/bis acrylamide gel. In both 
cases, the bands were visualized by ethidium bromide (Sigma) under an UV transilluminator. 
3.2.3. Neuropsychological assessment 
For the assessment of executive functions, the WCST was used (Heaton et al., 1993). 
Mean number of categories completed, number of perseverative errors, and failure to maintain 
set were the dependent variables. A simple word-list learning was used for the assessment of 
explicit verbal memory where the number of recalled words was the dependent measure (Gur 
et al., 2000). 
3.2.4. Data analysis 
Chi square (x2) tests were used to evaluate the differences in allele and genotype 
frequencies in the case of schizophrenia patients and controls, responders and non-responders, 
and patients with different degree of severity of cognitive dysfunctions. Analyses of variance 
(ANOVAs) were used to compare the neuropsychological performance of the patients with 
different genotypes. For post hoc comparisons, data were treated with Scheffe's tests. Clinical 
and demographic data were compared with two-tailed /-tests. The genotype frequencies were 
investigated with Fisher's exact test to test for Hardy-Weinberg equilibrium. 
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3.3. Brain-derived neurotrophic factor C270T polymorphism 
3.3.1. Subjects 
A total of 169 Caucasian volunteers participated in the study. Hundred and one of 
them (62 men and 39 women) received the DSM-IV diagnosis of schizophrenia. Their age 
was 39.8 ±11.8 years (mean ±SD). Sixty eight (39 men and 29 women) of them were healthy 
controls, age was 36.8 ±11.1 years (mean ±SD). Controls were recruited from the hospital 
staff and general population. Clinical symptoms were evaluated with the PANSS and the GAF 
scale. Participants also received the MINI Plus. A detailed overview of medical 
documentation (diagnosis, symptom ratings, and medication) was carried out by a psychiatrist 
who was blind to the results of genotyping. In addition, each patient was interviewed 
individually. All participants gave their informed consent. 
3.3.2 Genetic analysis 
Genomic DNA was extracted from peripheral blood leukocytes. The PCR reaction 
(Progene, Techne Cambridge) was carried out with the following primers: 5'-CAG AGG 
AGC CAG CCC GGT GCG-3' and 5'-CTC CTG CAC CAA GCC CCA TTC-3'. A 100 ng 
sample of genomic DNA was amplified in 25 pi reaction mixture [1.1 mM MgCh (Boehringer 
Mannheim), 200 pM of each dNTP (dATP, dCTP, dGTP, dTTP) (Boehringer Mannheim), 1 
pM of each primer (Creative Lab), 1.5 U/25 pi Taq polymerase (Sigma)]. The PCR program 
included the following steps: denaturation of DNA (5 min at 94°C), 30 cycles of 30 sec at 
94°C, 30 sec at 60°C, and 30 sec at 72°C. This was followed by the final extension for 5 min 
at 72°C. The PCR product was digested with Hinfi [5U/25 pi (Gibco)]. The electrophoresis 
was carried out on 8% acrylamide/bis acrylamide gel (BioRad). The bands were visualized by 
ethidium bromide (Sigma) under an UV transilluminator. 
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3.3.3. Data analysis 
The genotype frequencies were investigated with Fisher's exact test to test for Hardy-
Weinberg equilibrium. %2 test was used to evaluate the differences in genotype and allele 
frequencies in the schizophrenia patients and controls, and to evaluate gender distributions in 
the two experimental groups. The normality of data distribution was checked with 
Kolmogorov-Smirnov test. Student's /-test (two-tailed) was used to compare the clinical and 
demographical parameters. The level of statistical significance was defined as /?<0.05. 
4. Results 
4.1. Receptor functions 
The PANSS scores obtained form the high or low dose conditions did not show 
significant difference. There were no significant dose-dependent differences in the SAS and 
AIMS scores (Table 2). Significant dose-related differences in VCS were not observed either 
in the static (Figure 3) or dynamic conditions (Figure 4). 
Figure 3. Static contrast sensitivity under high and low dose conditions 
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Figure 4. Dynamic contrast sensitivity under high and low dose conditions 
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The striatal DRD2 receptor activity was found to be suppressed at the 1st 123I-IBZM 
SPECT investigation in 3 patients (patients No: 1, 4, 9) and normal in 7 patients by the visual 
evaluation (Table 3). In the 2nd investigation, contrary of decreasing the dose of quetiapine, 
the receptor occupancy increased in 4 (patients No: 3, 5-7), was unchanged in 3 (patients No: 
2, 8, 10) and decreased in 3 patients visually. The quantitative evaluation revealed 
individually different striatum/occipital ratios at the 1st and also at the 2nd investigation. The 
changes of the striatal I-IBZM uptake ranged from -27 to +35 %. The average uptake 
values of 123I-IBZM statistically did not differ between the 1st SPECT and the 2nd one (1.70 
±0.23 [mean ±SD] vs. 1.68 ±0.12 [mean ±SD]). In 5 subjects the values of striatum/occipital 
ratio increased and in 5 persons decreased during lowering the dose of quetiapine. From the 5 
patients with increased D2 receptor occupancy, each patient showed a relapse of acute 
schizophrenic episode which was not seen in patients with decreased receptor occupancy. We 
defined relapse as the worsening of psychotic symptoms which requires escalation of dose of 
maintenance therapy or change of antipsychotic therapy. The initial striatum/occipital ratio 
was significantly higher in patients with relapse compared to the others (1.86 ±0.17 [mean 
±SD], 1.53 ±0.15 [mean ±SD], p<0.01). The D2 receptor occupancy changes correlated with 
the time interval until the relapse (p<0.01), but not with the PANSS changes or with initial 
123I-IBZM uptake ratios. 
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Table 3. Results of the 123I-IBZM SPECT investigations in schizophrenic patients treated with 
quetiapine 
Patient 
No. 
Visual evaluation of DRD2 
occupancy 
Semiquantitative evaluation 
(striatal/occipital ratio) 
1st day 2nd day 
T day 2"u day Changes 
% R L R L 
1. decreased decreasing 1.44 1.33 1.69 1.48 29 
2. normal unchanged 1.74 1.66 1.67 1.71 1 
3.* normal increasing 2.20 2.10 1.81 1.86 -29 
4. decreased decreasing 1.48 1.56 1.79 1.78 35 
5.* normal increasing 1.81 1.62 1.59 1.52 -19 
6.* normal increasing 1.87 1.81 1.78 1.61 -15 
7.* normal increasing 1.81 1.81 1.58 1.55 -27 
8.* normal unchanged 1.85 1.76 1.87 1.58 -9 
9. decreased decreasing 1.38 1.37 1.53 1.61 29 
10. normal unchanged 1.61 1.72 1.69 1.81 5 
* patients showing symptoms of relapse during follow-up 
4.2. Dopamine D3 receptor Ser9Gly polymorphism and dopamine transporter VNTR 
polymorphism 
Table 4 shows the genotype and allele frequencies of the DRD3 S/G polymorphism in 
responder and non-responder patients with schizophrenia and controls. First, neither any 
specific genotype nor a particular allele was associated with schizophrenia when compared 
with the controls (¿>>0.3). In contrast, the S/S genotype was more frequent among the non-
responders than in the responders (x = 9.71, £#=1, ¿>=0.0018). A similar association was found 
when the S allele was taken into consideration (x2=5.68, <#=1, ¿>=0.0172). 
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Table 4. Genotype and allele frequencies of the dopamine D3 receptor (DRD3) S/G 
polymorphism in the responder and non-responder patients with schizophrenia and controls 
S/S S/G G/G S G 
Responders 
(n=47) 
13 (0.28) 34 (0.72) 0 60 (0.64) 34 (0.36) 
Non-
responders 18(0.64) * 10(0.36) 0 46 (0.82) * * 10(0.18) 
(n=28) 
Controls 
(n=45) 
22 (0.49) 22 (0.49) 1 (0.02) 66 (0.73) 24 (0.27) 
*p= 0.0018; * * p= 0.0172 
Table 5 shows the genotype and allele frequencies of the DAT VNTR polymorphism in the 
responder and non-responder schizophrenia patients and controls. None of the genotypes or 
alleles were associated with schizophrenia (p>0.5), and none of them were more frequent in 
responder or non-responder patients (/?>0.1). 
Table 5. Genotype and allele frequencies of the dopamine transporter (DAT) VNTR 
polymorphism in the responder and non-responder patients with schizophrenia and controls 
10/10 10/9 9/9 10 9 
Responders 
(n=47) 
27 (0.58) 18(0.38) 2 (0.04) 72 (0.77) 22 (0.23) 
Non-
responders 12(0.43) 13 (0.46) 3 (0.11) 37 (0.66) 19(0.34) 
(n=28) 
Controls 
(n=45) 
24 (0.53) 18(0.40) 3 (0.07) 66 (0.73) 24 (0.27) 
Table 6 depicts the clinical, demographical, and neuropsychological results as a function of 
genotypes. There was no significant difference among the subgroups in age, education, 
PANSS positive, negative, global symptoms, and GAF scores (/-test, p>0.1). An ANOVA 
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comparing the patients with S/S and S/G genotypes (n=36) and the controls (n=20) for the 
WCST categories completed indicated a significant main effect (F(2,53)=20.58,/?<0.0001). 
Table 6. Clinical, demographical, and neuropsychological characteristics of the patients of 
schizophrenia with different genotypes and control subjects 
Controls DRD3 S/S DRD3 S/G DAT 10/10 DAT 9/10 
Age (years) 36.4(12.8) 37.6 (9.7) 38.1 (11.8) 34.5 (9.8) 35.8(11.6) 
Education 
(years) 
10.0(2.4) 10.9(3.5) 10.9(2.6) 11.0 (2.9) 11.0 (3.2) 
WCST cat 5.2(1.0) 2.3 (1.1) 3.8(1.7) 3.4(1.7) 3.2(1.6) 
WCST pers 9.2 (4.7) 30.0(10.6) 19.7(12.0) 21.1 (12.5) 25.6(11.7) 
WCST set 0.7 (0.3) 1.0 (0.5) 0.8 (0.4) 0.8 (0.5) 1.0 (0.6) 
VR 15.7(3.7) 9.6 (3.7) 9.9 (5.2) 9.8 (4.5) 9.3 (5.0) 
GAF - 47.3 (19.4) 53.2(16.9) 51.6(19.1) 49.8(18.0) 
PANSS P - 20.2 (7.8) 20.6 (8.4) 21.4 (8.0) 19.5 (8.3) 
PANSS N - 24.4 (7.9) 24.1 (6.0) 24.8 (6.8) 23.7(7.3) 
PANSS G - 46.4(13.6) 46.2(15.0) 48.3 (14.6) 44.3 (14.4) 
Data are mean (standard deviation). DRD3 - dopamine D3 receptor, DAT - dopamine 
transporter, WCST - Wisconsin Card Sorting Test, cat - categories completed, pers - number 
of perseverative errors, set - failure of maintaining a set, VR - verbal recall, GAF - Global 
Assessment of Functioning, PANSS - Positive and Negative Syndrome Scale, P - positive 
symptoms, N - negative symptoms, G - general symptoms 
Both schizophrenia subgroups completed fewer categories in comparison with the 
controls (p<0.005). In addition, the patients with S/S genotype completed fewer categories 
than the patients with S/G genotype (p<0.01). Similar results were obtained for the WCST 
perseverative errors (main effect of group: F(2,53)=20.58, /?<0.0001; controls vs. 
schizophrenia: /?<0.005; S/S vs. S/G: /><0.01). In contrast, no group effect was found in the 
case of WCST failure to maintain set (/?>0.1). Finally, in the case of verbal recall 
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schizophrenia patients again showed an impaired performance (main effect of group: 
F(2,53)=14.76,/?<0.0001; post hoc comparison: /?<0.0005), but the S/S and S/G subgroups did 
not differ significantly (p>0.5) (Figure 5). Homologous analyses for the DAT genotypes 
confirmed that the patients with schizophrenia were impaired irrespective to the VNTR 
polymorphism (p<0.005). We found no significant difference between the subgroups with 
10/10 and 9/10 genotypes. Overall, there was no significant difference between the 
performance of male and female participants (p>0.5). 
Figure 5. Gene effect of DRD3 Ser9Gly polymorphism on executive and explicit memory 
functions in schizophrenic patients 
CAT PERS SET MEM 
-«- S-S 
S-G 
CAT - categories completed, PERS - number of perseverative errors, SET - failure of 
maintaining set, MEM - explicite memory, S-S - Ser9Ser genotype, S-G - Ser9Gly genotype 
* = p < 0 . 0 1 
To further elucidate the significant difference between the S/S and S/G schizophrenia 
patients, the participants of these subgroups were divided according to the severity of 
cognitive dysfunctions. In the case of WCST categories, 20 patients showed severe 
impairment (>2 SD below the control mean) from which 13 had S/S and 7 had S/G genotype. 
In the moderately impaired group (n=8) (1-2 SD below the control mean), 2 patients had SS 
and 6 patients had SG genotype. Most notably, in the remainder well-performing group (n=8) 
(<1 SD below the control mean) each subject was characterized with S/G alleles. Thus, the 
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S/S genotype was over-represented in the most severely affected group in comparison with the 
moderately affected group (x =3.63, df= 1, ¿>=0.0552) and with the well-performing 
schizophrenia patients (x =9.31, df=\, ¿>=0.0013). Analogous analyses concerning the WCST 
perseverative errors yielded similar results (severely impaired (n=18): 12 S/S, 6 S/G; 
moderately impaired (n=12): 3 S/S, 9 S/G; well-performing (n=6): 0 S/S, 6 S/G). Again, the 
S/S genotype was more frequent in the patients with the worst performance compared with the 
moderately dysfunctional group (x2=5.00, df= 1, ¿>=0.0254) and with the well-performing 
. 9 • • • 
patients 
(X-8.60, df= 1, ¿>=0.0047). In the 
case of explicit memory, a similar portion of 
patients showed severe disturbances as in the WCST (n=19), but the distribution of S/S and 
S/G genotypes was more balanced (8 S/S and 11 S/G), and did not differ significantly from 
the moderately impaired (n=7; 3 S/S, 4 S/G) and well-performing (n=10; 4 S/S, 6 S/G) 
subgroups (p>0.5). 
4.3. Brain-derived neurotrophic factor C270T polymorphism 
The genotype distributions for the patient and control groups were not significantly 
deviated from the Hardy-Weinberg equilibrium. Regarding the genotype frequency, the C/T 
genotype was overrepresented in the schizophrenia patients (25.7%) compared with the 
controls (5.9%) (x2=11.17, df=\, ¿7=0.0008). Similarly, the 270T allele was more frequent in 
the patients (13.9%) than in the controls (2.9%) (%2=11.31, z^ l ,p=0 .0008) (Table 7). 
Table 7. Genotype and allele frequencies of the brain-derived neurotrophic factor (BDNF) 
C270T polymorphism in patients with schizophrenia and controls 
Genotype Alleles 
C/C T/C T/T C T 
Patients 
n=101 
74 (73.3%) 26 (25.7%)* 1 (1.0%) 174 (86.1%) 28(13.9%)* 
Controls 
n=68 
64 (94.1%) 4 (5.9%) 0 (0%) 132 (97.1%) 4 (2.9%) 
* ¿7=0.0008 
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In the patient group, the mean value for PANSS positive symptoms was 19.4 
(S.D.=8.2), for negative symptoms, 24.1 (S.D.=8.4), and for global symptoms, 46.5 
(S.D.=17.9). The mean GAF score of the patients was 44.2 (S.D.=17.9). There was no 
significant difference in PANSS items and GAF scores between the patients with C/C and C/T 
genotypes (p>0.4, /-test). The patient and the controls did not differ in age (p=0.10, /-test). 
Similarly, the gender distribution was similar in both groups (p=0.60, %2test). 
5. Discussion 
5.1. Receptor functions 
Our results from clinical examination (extrapyramidal scales), l23I-IBZM SPECT 
investigation, and VCS measurement uniformly proved that the atypical antipsychotic 
quetiapine does not induce pronounced DRD2 blockade even when higher doses are 
administered. It is a well-known view that DRD2 blockade modulates the antipsychotic effect 
of treatment (Klemm et al., 1996) and neuroleptic induced extrapyramidal symptoms are also 
quantitatively related to DRD2 occupancy (Farde et al., 1992). Accordingly, the receptor 
binding propensity of an antipsychotic agent is a reliable predictor of its potential to induce 
extrapyramidal symptoms (Tauscher et al., 2002). Classical antipsychotics cause a higher DA 
blockade even at lower doses, while atypical compounds tend to generate only low striatal 
DRD2 blockade. Other atypicals like risperidone or olanzapine may cause DRD2 occupancy 
above 75 % in a dose dependent manner; however the frequency of extrapyramidal symptoms 
remains rare. It could be explained by the high 5HT2/DA affinity ratio which attributes almost 
every novel antipsychotic: the blockade of serotonin receptors could enhance DA transmission 
and thus decreases the risk of extrapyramidal symptoms (Meltzer, 1995). 
According to a recently published hypothesis, the advantageous effect/side effect 
profile of atypical antipsychotics can be explained by a common mechanism. These drugs can 
be characterized by only transiently high DRD2 occupancy and then a fast dissociation from 
the receptor (Kapur & Remington 2001). In this context, different VCS results from studies 
including patients who received different antipsychotic agents could be well explained. Drugs 
with high DRD2 affinity cause reduced VCS as it can be observed in patients with Parkinson's 
disease, but atypical antipsychotics do not have such detrimental effects (Kéri et al., 1999). 
Although VCS is influenced by many factors (optic properties of the eye, photoreceptor 
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functions, age, attention etc.), we consistently found that dopaminergic status of the visual 
system is a major determining factor (Kéri et al., 2000, 2002). The site of action is dubious; 
the retina and the lateral geniculate nucleus are possible candidates. 
In the majority of our cases, after the introduction of quetiapine treatment, 
the first ,ZJI-
IBZM SPECT investigation showed low striatal DRD2 occupancy. During the observation 
period, in accordance with the low D2 receptor occupancy, none of the patients exhibited 
extrapyramidal symptoms. During the 6 months follow-up we observed clinical relapse in 5 
patients. Each of them showed decrease in S/O ratio in spite of dose decrease. 
The different levels of D2 receptor occupancy and receptor occupancy changes might 
depend on the individual dopaminergic status of the patients. In schizophrenia the 
dysregulation of dopamine system includes the lower level of tonic DA release and an 
exaggerated DA response to different stimuli such as stress and psychoactive substances 
(Weinberger et al., 1987; Grace, 1991). These subcortical anomalies show relationship with 
structural and functional impairments of the dorsolateral prefrontal cortex (Bertolino et al., 
2000). This complex disturbance of regulation is specific to active phases of the illness, 
including prodromal phase, psychotic states and subsequent relapses, which could last several 
months (Laruelle et al., 1999). The patient with actually stable state of illness does not show 
this neurochemical feature. In the active phase, stimuli can elicit increased dopamine release 
in the striatum, leading to a decrease in the S/O ratio during l23I-IBZM SPECT investigation 
(Laruelle, 2000). At the time of the 2nd investigation, all of our patients were in a clinically 
stable state. In patients showing relapse of symptoms during the follow-up phase, the 
persistent hyperresponsive state of the striatal dopaminergic system might explain the increase 
in receptor occupancy in spite of the decreased dose of antipsychotic medication, delineating a 
group of patients with a higher risk for relapse. Of course, this finding must be interpreted 
cautiously because of the small sample size. 
5.2. Dopamine D3 receptor Ser9Gly polymorphism and dopamine transporter VNTR 
polymorphism 
We investigated the distribution of DRD3 Ser9Gly and DAT VNTR polymorphisms 
between groups and the effect of these variants on therapeutic response and cognitive 
functions. We found the Ser9 allele and Ser9Ser genotype to be significantly more frequent 
among non-responders. The patients with Ser9Ser genotype showed poorer executive 
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performance than Ser9Gly genotype ones. We failed to show any association regarding the 
DAT VNTR variants. Our results referring to the effect of Ser9Gly polymorphism on 
therapeutic response are in congruence with two previous trials investigating patients on 
clozapine therapy (Shaikh et al., 1996; Scharfetter et al., 1999), but are more robust which 
may be due to the inclusion of patients receiving other atypical antipsychotics. These 
compounds are different in their pharmacodynamic and clinical properties due to their 
multireceptorial action, which could lead to more pronounced association with a poorer 
treatment response when a particular DRD3 variant is present. 
The association of poorer WCST performance with DRD3 Ser9Ser genotype in 
schizophrenia is of particular interest. This phenomenon was restricted to the executive 
components of the task. The failure to maintain set was not impaired in the patients, which 
suggests that they successfully stayed on task. Moreover, the patients with Ser9Ser and 
Ser9Gly genotypes showed statistically indistinguishable performances in the explicit memory 
task. This suggests two important possibilities. First, the Ser9Ser patients are not likely to 
display a markedly impaired WCST performance simply because of a more severe generalized 
cognitive deficit in comparison with the Ser9Gly patients. It is also notable that these two 
schizophrenia subgroups did not differ in demographic parameters and GAF/PANSS-scores, 
which suggests that poorer therapeutic response and executive dysfunctions are not simple 
consequences of a more severe psychopathology. Second, the contribution of DRD3 
polymorphism to the prefrontal executive system seems to be quite specific contrasting with 
the hippocampal explicit memory system. The finding that patients with Ser9Ser genotype 
may show poorer prefrontal functions is also supported by the data of Rybakowski et al. 
(2001) who found that fixation and smooth pursuit eye movement disturbances were higher in 
schizophrenia patients with this genotype, since eye movement dysfunctions are often linked 
to prefrontal pathology (O'Driscoll et al., 1999). Considering another component of the 
dopaminergic system, Egan et al. (2001) demonstrated that the high-activity Val allele of the 
COMT gene predicted poorer WCST performance and less efficient prefrontal activation. The 
Val allele is also related to attentional impairment, slower psychomotor speed (Bilder et al., 
2002), eye movement disturbances (Rybakowski et al., 2002), and abnormalities of the P300 
component of event-related potentials (Gallinat et al., 2003). 
Egan et al. (2001) also suggested that the DAT might play a less important role in 
prefrontal functions because of its low density therein. This hypothesis was confirmed by the 
present results, which indicated no significant WCST difference between the patients with 
distinct DAT genotypes. 
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5.3. Brain-derived neurotrophic factor C270T polymorphism 
The results of this study demonstrated an association of schizophrenia and T270 
variant of BDNF gene. This finding is consistent with the data of a Japanese group (Kunugi et 
al., 2003). BDNF is a member of trophic factors with a notably complex role in the normal 
development of nervous system (Thoenen 1991). One of its most important effects is the 
modulation of DA system: BDNF secreted by midbrain dopaminergic neurons regulates the 
expression of DRD3 in the nucleus accumbens and hence controls the responsiveness of these 
neurons to DA which is a fundamental aspect of neuronal plasticity (Guillin et al., 2001). It is 
presumable that genetic variants of the BDNF have altered function and effects on 
developmental events. For example, a single nucleotide substitution (A758G) causing Val/Met 
substitution at codon 66 in the BDNF gene affects intracellular distribution, packaging, and 
release of the BDNF protein in vitro. Furthermore, in humans, this polymorphism has 
significant effects on verbal episodic memory, hippocampal physiological activation, and 
measures of hippocampal neuronal integrity and synaptic abundance (Egan et al., 2003). 
These facts made BDNF to be a candidate gene for schizophrenia. Studies focusing on the 
dinucleotide repeat polymorphism of BDNF found negative results (Hawi et al., 1998; Krebs 
at el., 2000; Virgos et al., 2001; but see Muglia et al., 2003), similarly to that of investigating 
the Val66Met variant (Egan et al., 2003). The C270T single nucleotide substitution (Kunugi et 
al., 2001) has recently been reported to be more frequent in schizophrenia comparing to 
controls (Kunugi et al., 2003), with only weak significance in respect of mutant T270 allele 
(p=0.037) and C270T heterozygote status (p=0.034) as well. In our sample, the association 
was statistically more significant (p=0.008) and the heterozygote status was more common in 
the controls (4.5% vs. 5.9%), which can be the consequence of differences of allele 
distributions between races. Further studies are warranted to replicate these findings and 
further trials should clarify the functional consequences of the BDNF C270T polymorphism 
regarding the etiology and clinical characteristics of schizophrenia. 
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5.4. Final conclusions 
We investigated certain functional and genetic aspects of central DA system in 
schizophrenia. Here we demonstrated the favorable effect of atypical antipsychotic quetiapine 
on DA system, and delineated a group of patients with higher risk for relapse using clinical 
rating scales, visual contrast sensitivity measurement and visualisation of striatal DRD2 
occupancy. We presented relationship between cognitive impairments as well as therapeutic 
response and DRD3 Ser9Gly polymorphism. And last we found an association between 
BDNF C270T polymorphism and schizophrenia. 
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